Yifang Biotech: D-2570 approved in the United States to conduct Phase II clinical trials for psoriasis

K-LinePoet · 2026-04-06T20:00:21+00:00

Yifang Bio announced that the company's application for a Phase II clinical trial of D-2570 as a monotherapy for psoriasis (PsO) submitted to the U.S. Food and Drug Administration (FDA) has recently reached the 30-day default period without receiving any objections from the FDA. According to relevant regulations, D-2570's Phase II clinical trial as a monotherapy for PsO in the United States has officially been approved.

K-LinePoet

2026-04-06 20:00:21

Yifang Biopharma announced that the company’s Phase II clinical trial application submitted to the U.S. Food and Drug Administration (FDA) for D-2570 monotherapy to treat psoriasis (PsO) has recently reached the 30-day default period and no objections from the FDA have been received. According to the relevant regulations, the Phase II clinical trial of D-2570 in the U.S. for monotherapy treatment of PsO has been officially approved.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes